Back to company

ZYMENEX ApS: Financial statements 2016

CVR: 27394752

ZYMENEX ApS (CVR 27394752) has filed annual accounts for 2016. In 2016, the company reported revenue of DKK 49,052,000 and a net result of DKK 294,360,000 compared with DKK 656,421 the year before. The profit margin was 600.1%. Equity amounted to DKK 230,260,000. The solvency ratio was 64%.

Revenue
49,052,000 kr.
Gross Profit
49,052,000 kr.
Profit/Loss
294,360,000 kr.
Equity
230,260,000 kr.
Total Assets
360,029,000 kr.

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
201649.1 mio.49.1 mio.294.4 mio.230.3 mio.-
2015--52.5 mio.656 t.-64.1 mio.-
2014--67.9 mio.1.1 mio.-64.8 mio.-
2013---33.8 mio.-65.8 mio.-
2012---42 mio.-32.1 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is ZYMENEX ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2016

Natallia Misuna leaves the board of ZYMENEX ApSJul 29, 2016

As of July 29, 2016, Natallia Misuna has left the board of directors of ZYMENEX ApS.

ZYMENEX ApS appoints new auditorMay 17, 2016

As of May 17, 2016, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ZYMENEX ApS.

Auditor steps down at ZYMENEX ApSMay 17, 2016

As of May 17, 2016, KPMG P/S has stepped down as auditor of ZYMENEX ApS.

ZYMENEX ApS: The 2015 annual report is outMay 13, 2016

ZYMENEX ApS has published its annual report for 2015. Gross profit came to DKK -52,501,446, and the net result was DKK 656,421.

About ZYMENEX ApS

ZYMENEX ApS was a Danish company of the type Anpartsselskab based in København Ø, founded in 2003 and dissolved in 2019. The company was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi. The company has 1 employee. In 2018, the company reported revenue of DKK 10,758,000 and a net result of DKK 1,292,000 compared with DKK 3,404,000 the year before. Equity amounted to DKK 82,550,000.

Other financial years